Browse News
Filter News
Found 804,898 articles
-
Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study
3/19/2024
Asieris Pharmaceuticals announced that the multicenter Phase III global clinical study data of its non-surgical treatment for cervical HSIL product APL-1702 demonstrated significant efficacy and good safety profile, with new advancements in clearance rate of high-risk HPV16 and/or HPV18.
-
Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC
3/19/2024
Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement.
-
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
3/19/2024
Innovent Biologics, Inc. announced that the primary endpoint has been met in the second Phase 2 clinical study of efdamrofusp alfa high-dose, a recombinant human VEGFR-Fc-Human CR1 fusion protein injection, in Chinese subjects with neovascular age-related macular degeneration.
-
Cognizant to apply generative AI to enhance drug discovery for pharmaceutical clients with NVIDIA BioNeMo
3/19/2024
Cognizant is advancing the application of generative AI technology with the NVIDIA BioNeMo platform to solve complex challenges of drug discovery in the life sciences industry, such as improving productivity in the development process and increasing the speed at which new, life-saving treatments can be brought to market.
-
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
3/19/2024
Madrigal Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant.
-
Innate Pharma Announces Its Participation to Upcoming Investor Conference - March 19, 2024
3/19/2024
Innate Pharma SA announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.
-
ObsEva Announces Update on Board of Directors - March 19, 2024
3/19/2024
ObsEva SA announced that, concurrent to the decision to wind-down the company’s operations, Catarina Edfjäll, Ph.D. has decided to step down from the Board effective today.
-
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
3/19/2024
AstriVax is pleased to welcome Dr. Gregory Fanning as its Chief Business Officer.
-
BioSpace's 2024 Salary Report explores the average salaries and salary trends of life sciences professionals.
-
AstraZeneca reported Monday that adding Lynparza to Imfinzi improved outcomes in mismatch repair proficient endometrial cancer, more than doubling the median duration of response in patients.
-
New late-stage trial results for GSK’s Jemperli show improved overall and progression-free survival in a broader range of endometrial cancer patients, which could lead to a potential label expansion.
-
Contineum Therapeutics joined the 2024 initial public offering class on Friday with an SEC filing. The biotech will use the IPO proceeds to complete a Phase II trial for its most mature candidate targeting multiple sclerosis.
-
Following GSK’s lead, Pfizer plans to lower its interest in Haleon from 32% to approximately 24%, with the sale of 630 million ordinary shares in the consumer healthcare spinoff.
-
With Boehringer Ingelheim’s announcement earlier this month that it was capping U.S. inhaler costs at $35 per month, AstraZeneca on Monday followed suit.
-
The FDA will close out a hectic month of March with a flurry of target action dates, including ones for lymphoma and CKD anemia treatments.
-
With its FDA approval last week and first-to-market advantage, Madrigal Pharmaceuticals’ Rezdiffra will set the standard for other metabolic dysfunction-associated steatohepatitis candidates in development.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Knowing that you want to integrate AI is one thing—but how do you actually do it? For biotech companies kickstarting their generative AI journey, here are four things to consider.
-
Kindeva Drug Delivery Welcomes Jennifer Riter, New Vice President of Analytical Services
3/18/2024
Kindeva Drug Delivery, a global leader in drug-device combination products, welcomes Jennifer Riter as Vice President of Analytical Services to head up the recently announced analytical services global business unit.